Moses Owoicho Abah | Bioinformatics in Pharmaceuticals | Best Researcher Award

Published on 16/07/202516/07/2025 by Top Pharmaceutical

Moses Owoicho Abah | Bioinformatics in Pharmaceuticals | Best Researcher Award

Dr. Moses Owoicho Abah at World-Class Research Center “Digital biodesign and personalized healthcare”, Sechenov First Moscow State Medical University, Moscow, Russia, Russia.

Dr. Moses Owoicho Abah is a passionate cancer researcher and molecular oncologist 🧪, currently pursuing a Ph.D. in Oncology/Radiation Therapy 🎓 at I.M. Sechenov First Moscow Medical University. With academic roots in Biochemistry, Bioinformatics, and Medical Biochemistry 🧠, he specializes in RNA sequencing, immunoassays, and biomarker discovery. Dr. Abah has worked across leading institutions in Nigeria and Russia 🇳🇬🇷🇺, contributing to drug discovery, genomics, and personalized oncology. He brings deep expertise in data analysis using Python and R 📊, and his impactful research is published in Scopus-indexed journals 📚. His goal is to revolutionize cancer treatment globally.

Publication Profile

Google Scholar

Education

Dr. Moses Owoicho Abah’s educational path reflects his unwavering dedication to biomedical sciences and cancer research 🧬. He is currently pursuing a Ph.D. in Oncology/Radiation Therapy (2022–2025) at the Institute for Personalized Oncology, I.M. Sechenov First Moscow Medical University 🇷🇺. He earned his M.Sc in Medical Biochemistry (2020–2022) from the University of Abuja 🇳🇬 and completed a Professional Program in Bioinformatics (2019–2020) at MIPT, Russia. His foundation lies in a B.Sc (Hons) in Biochemistry (2010–2015) from FUAM and a Senior School Certificate from GSS Otukpo (2002–2007) 📚. His journey blends science, research, and innovation.

Experience

Since February 2025, Dr. Moses Owoicho Abah has served as a Cancer Research Coordinator at the Genetics, Genomics, and Bioinformatics Department of the National Institute for Cancer Research and Treatment, Nigeria 🇳🇬. He collaborates closely with the Principal Investigator to uphold global research standards 🌍, prepares proposals, budgets, protocols 📄, and handles informed consent and participant screening ✅. Skilled in RStudio and Python 📊🐍, he generates complex data visuals, manages study supplies, and maintains communication with stakeholders. He also revises and submits manuscripts to top journals 📚, contributing meaningfully to global cancer research.

Awards

Dr. Moses Owoicho Abah has received multiple prestigious awards for his excellence in research and academics 🎓. In July 2021, he was honored with the Associate Fellow Award (CMRf-Bioinformatics) by the Royal Society of Clinical and Academic Researchers of Nigeria (ROSCARON) 🧬. In February 2020, he emerged Overall Best Scholar in Clinical Medicine, Chemistry & Biology during the Russian Open Door Scholarship competition 🇷🇺. Earlier, in August 2018, he was conferred an Honorary Fellow Award by the Association of Economists and Statisticians of Nigeria (AESN) 📈—a testament to his cross-disciplinary brilliance.

Research Focus

Dr. Moses Owoicho Abah’s research lies at the intersection of oncology, molecular medicine, and bioinformatics 🧪. His work focuses on cancer biology, particularly angiogenesis, cytokine signaling, and drug resistance mechanisms in lung and renal cancers 💉🩸. He explores innovative therapies targeting biomarkers using comparative transcriptomics and RNA sequencing for precision medicine. Additionally, he investigates the toxicological effects of everyday compounds, such as triclosan 🧼, and their impact on hormonal balance. His studies also include natural product pharmacology and the anti-diabetic potential of medicinal plants 🌿, bridging traditional medicine with modern therapeutic strategies.

Publication Top Notes

Nigatu Gebrehiwot | Precision Medicine | Best Researcher Award

Published on 22/04/202522/04/2025 by Top Pharmaceutical

Nigatu Gebrehiwot | Precision Medicine | Best Researcher Award

Dr. Nigatu Gebrehiwot, Zhengzhou University, China

Dr. Nigatu Gebrehiwot is a dedicated PhD candidate in Pharmacology at Zhengzhou University, China, specializing in drug safety evaluation. He holds a Master’s in Clinical and Administrative Pharmacy from Xi’an Jiaotong University and a Bachelor of Pharmacy from Mekelle University, where he was recognized as an outstanding student. A published researcher and global presenter, Dr. Gebrehiwot has earned accolades including recognition at ISPOR in Barcelona. He is actively involved in multiple international scientific societies and brings strong expertise in pharmacotherapy, academic writing, and collaborative healthcare research. His work explores methionine metabolism and innovative therapeutic strategies.

Publication Profile

Orcid

Education

Dr. Nigatu Gebrehiwot holds a Master’s degree in Clinical and Administrative Pharmacy from Xi’an Jiaotong University, where his research earned an award at the 21st European Congress ISPOR Health Outcome Research Conference in Barcelona, Spain. 🏅 He also earned a Bachelor’s degree in Pharmacy from Mekelle University, where he was recognized as the most outstanding student in his class. 🎓 His academic achievements reflect his dedication to advancing the field of pharmacy, blending clinical expertise with research excellence. Dr. Gebrehiwot’s work continues to impact the healthcare landscape positively.

Experience

Dr. Nigatu Gebrehiwot is currently a Ph.D. candidate in Pharmacology at the Center for Drug Safety Evaluation and Research, Zhengzhou University, Henan, China, since September 2022. 🎓 Prior to this, he served as the Principal Scientific Officer at the Federal Ministry of Health (FMOH) in Ethiopia from June 2020 to 2021. During his tenure, Dr. Gebrehiwot managed national disease programs and medicines, overseeing the funding and evaluation of treatment guidelines and drug therapy protocols in accordance with Ethiopian legislation and EFDA guidelines. 💊 He also led technical committees focused on antimicrobial therapy, cancer, and chronic disease management.

Awards

Dr. Nigatu Gebrehiwot received a prestigious award for his research abstract at the 21st European Congress ISPOR Health Outcome Research conference in Barcelona, Spain. 🏆 This recognition underscores the significant impact of his work in the field of pharmacology and health outcome research. 🌍 His contributions continue to advance knowledge and influence healthcare practices, making him a respected figure in his field. 💡 Dr. Gebrehiwot’s dedication to research excellence and his ability to address critical health issues have earned him well-deserved acknowledgment on an international stage.

Research Focus

Dr. Nigatu Tadesse’s research primarily focuses on molecular alterations in disease processes, with an emphasis on metabolic pathways and their potential as diagnostic and therapeutic targets. His work on gastric intestinal metaplasia and methionine metabolism sheds light on novel approaches to diagnosis and treatment. Additionally, Dr. Tadesse has contributed significantly to pharmacology, particularly the study of traditional medicines like Dioscorea zingiberensis, investigating its phytochemistry, clinical applications, and toxicity. His research also extends to industrial processes, such as wastewater treatment in diosgenin production. His interdisciplinary work connects biomedicine, pharmacology, and environmental science.

Publication Top Notes

Molecular Alterations in Gastric Intestinal Metaplasia Shed Light on Alteration of Methionine Metabolism: Insight into New Diagnostic and Treatment Approaches

Knowledge, attitude and antibiotic prescribing patterns of medical doctors providing free healthcare in the outpatient departments of public hospitals in Sierra Leone: A national cross-sectional study

Dioscorea zingiberensis C. H. Wright: An overview on its traditional use, phytochemistry, pharmacology, clinical applications, quality control, and toxicity

First total synthesis of a novel amide alkaloid derived from Aconitum taipeicum and its anticancer activity

Methods to treat the industrial wastewater in diosgenin enterprises produced from Diosorea zingiberensis C. H. Wright

Safety investigation on total steroid saponins extracts from Dioscorea zingiberensis C.H. Wright: Sub-acute and chronic toxicity studies on dogs

Alessandra Tucci | Personalized Medicine | Women Researcher Award

Published on 03/04/202503/04/2025 by Top Pharmaceutical

Alessandra Tucci | Personalized Medicine | Women Researcher Award

Dr. Alessandra Tucci, ASST Spedali Civili di Brescia, Italy

Dr. Alessandra Tucci is an esteemed Italian hematologist and Director of the Hematology Unit at ASST Spedali Civili di Brescia. With over three decades of expertise, she specializes in lymphomas, particularly in elderly patients. She holds dual specializations in Allergology & Immunology (University of Florence) and Hematology (University of Milan). A key figure in national and international research, she has led multiple clinical trials and serves on prestigious scientific boards, including the Italian Lymphoma Foundation (FIL) and European Hematology Association (EHA). An accomplished author and peer reviewer, Dr. Tucci continues to advance hematological research.

Publication Profile

Scopus

Education

Dr. Alessandra Tucci 🎓 earned her Doctor of Medicine degree from the University of Brescia in 1987, specializing in Allergology, Immunology, and Hematology. 🩸 Her dual specialization underscores her deep expertise in blood disorders and immune-related conditions. 🏥 Passionate about advancing medical science, she further pursued a Master’s in Management applied to hematology, showcasing her leadership in clinical and research settings. 📚 With a strong foundation in both patient care and scientific innovation, Dr. Tucci continues to make significant contributions to the field, bridging the gap between medical research and practical healthcare solutions. 🔬✨

Experience

Dr. Alessandra Tucci 🔬 is a Principal Investigator in numerous national and international studies, focusing on hematology, particularly lymphomas and hematologic malignancies in elderly patients. 🩸 Her research impact is evident through an impressive H-index of 44 (Scopus) and 48 (Google Scholar), with over 9,792 citations. 📊 She has contributed as a Guest Editor for Special Issues in high-impact journals like Cancers and serves as a reviewer for prestigious publications such as Lancet Haematology and Blood Advances. 📖 Her dedication to advancing hematologic research continues to shape the field and improve patient outcomes worldwide.

Awards

Dr. Alessandra Tucci 🏆 has played a pivotal role in clinical trials (phases I-III), driving innovative treatments in hematology and significantly improving patient care. 🩸 Her contributions extend beyond research, as she actively shapes the scientific community through editorial work, peer reviews, and participation in prestigious scientific boards. 📖🔬 Recognized for her expertise and leadership, she is a respected thought leader whose work influences both clinical practice and future therapeutic advancements. 🌍✨ Through her dedication, Dr. Tucci continues to leave a lasting impact on the field of hematology, inspiring researchers and improving patient outcomes worldwide. 💡👩‍⚕️

Research Focus

Dr. Alessandra Tucci is a distinguished researcher specializing in hematology 🩸, with a focus on lymphomas 🦠, leukemias 🧬, and stem cell transplantation 🏥. Her work extensively explores invasive pulmonary aspergillosis in leukemia, mantle cell lymphoma prognosis, and the impact of radiotherapy on hematologic malignancies. She contributes to clinical trials, geriatric oncology assessments, and advanced imaging techniques like FDG PET/CT 📡 to improve diagnostic precision and treatment outcomes. Dr. Tucci’s research plays a critical role in optimizing chemoimmunotherapy 💉 and personalized medicine for hematologic disorders.

Publication Top Notes

Different Epidemiology of Invasive Pulmonary Aspergillosis in Acute Lymphoblastic Leukemia in Comparison With Acute Myeloid Leukemia: Results of a Prospective Multicentric Observational Study of the Rete Ematologica Lombarda

Impact of the Number of Administered Systemic Treatment Lines on Local Response to Radiation Therapy for Multiple Myeloma

A phase 2 study of autologous stem cell transplantation as salvage therapy for older patients with aggressive B-cell lymphoma prospectively evaluated by comprehensive geriatric assessment: the FIL_RECANZ study

Prognostic Role of Pretreatment Tumor Burden and Dissemination Features From 2-[¹⁸F]FDG PET/CT in Advanced Mantle Cell Lymphoma

Early progression beyond first-line chemoimmunotherapy in follicular lymphoma: Insights from a Fondazione Italiana Linfoma (FIL) study

Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results

Correction: Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19 (Genome Medicine, (2023), 15, 1, (22), 10.1186/s13073-023-01173-8)

Lack of association between classical HLA genes and asymptomatic SARS-CoV-2 infection

Local radiotherapy and measurable residual disease-driven immunotherapy in patients with early-stage follicular lymphoma (FIL MIRO): final results of a prospective, multicentre, phase 2 trial

2-[¹⁸]F FDG PET/CT dissemination features in adult burkitt lymphoma Are predictive of outcome

nisreen kaddim | Drug Delivery Systems | Best Innovation Award

Published on 12/03/202512/03/2025 by Top Pharmaceutical

nisreen kaddim | Drug Delivery Systems | Best Innovation Award

Dr. nisreen kaddim, Ministry of Higher Education and Scientific Research, University of Babylon, Iraq

Dr. Nisreen Kaddim Radi is an Assistant Professor at the University of Babylon, specializing in molecular biology, genetics, PCR, and virology 🧬. Her research focuses on antimicrobial resistance, food safety, and innovative antibacterial films for medical applications 🏥. She has presented at international conferences and published extensively in high-impact journals 📚. Passionate about advancing science, she integrates computational and experimental approaches to explore anticancer and antibacterial agents ⚗️. With a commitment to research and education, Dr. Nisreen inspires students and contributes to scientific innovation 🌍.

Publication Profile

Google Scholar

Professional Background

Dr. Nisreen Kaddim Radi 🎓 is an Assistant Professor at the College of Science for Women, University of Babylon, specializing in molecular biology, genetics, PCR, and virology 🦠, with a focus on food safety and packaging 🍱. She is a member of the Arab Association for Science and Technology, Iraq branch, and serves on the Educational Guidance Committee at her college. Dr. Nisreen has published numerous research papers and actively participates in global conferences 🌍, including the 2022 International Conference on Sustainable Development Goals in Istanbul, ICAB 2022 at the University of Basrah, and ICAB2 2024, where she presented her studies on antimicrobial resistance, genetic variation, and immunological research

Memberships

Dr. Nisreen Kaddim Radi 🔬 is a dedicated researcher with significant contributions to molecular biology, genetics, and virology 🧬. Although she does not hold editorial positions or industry collaborations, her active engagement in scientific research strengthens her impact in the field. As a member of the Arab Association for Science and Technology 🌍, she remains connected to a network of experts, enhancing her academic and professional credibility. Through her research and participation in international conferences, Dr. Nisreen continues to contribute valuable insights to the scientific community, particularly in food safety and antimicrobial resistance 🦠.

Innovation in Methodology

Dr. Nisreen Kaddim Radi 🔬 combines computational simulations with experimental studies to develop innovative methods for enhancing the effectiveness of antibacterial and anticancer agents 🦠🎗️. Her dual-approach methodology integrates cutting-edge technology with practical applications, demonstrating a high level of scientific innovation 🚀. By bridging computational modeling with real-world experimentation, she contributes to advancing medical and pharmaceutical research, aligning perfectly with the award’s objectives 🏆. Her work not only improves therapeutic outcomes but also paves the way for more efficient and targeted treatments, reinforcing her role as a leading researcher in molecular biology and biotechnology 🧬.

Research Excellence

Dr. Nisreen Kaddim Radi 🔬 is pioneering the development of antibacterial films by integrating nanomaterials, polymers, and plant extracts 🌱🦠. Her innovative approach has profound implications for both medical and industrial applications 🏥🏭, positioning her at the forefront of antibacterial and anticancer material research 🎗️. Her groundbreaking study, Integrative Computational and Experimental Study of Propolis, Polyvinyl Alcohol, and Alhagi maurorum Complex as Anticancer and Antibacterial Agents 📜, showcases a multidisciplinary methodology, blending computational modeling with experimental validation 💻⚗️. This research enhances therapeutic potential, contributing to the advancement of novel biomedical materials and precision-targeted treatments 🚀.

Research Focus

Dr. Nisreen Kaddim Radi’s research primarily focuses on medical microbiology 🦠, immunology 🧬, and infectious diseases 🏥. Her work extensively explores viral infections such as Varicella Zoster Virus (VZV) 🏵️, Human Papillomavirus (HPV) 🎗️, and Hepatitis B Virus (HBV) 🦠, investigating genetic susceptibility and immune response. She also examines bacterial resistance 🧫, particularly in foodborne pathogens like E. coli, and studies immunological markers 🧪 in various infections. Her contributions in genetic polymorphisms 🔬, cytokine responses 🌡️, and molecular typing of pathogens highlight her expertise in understanding disease mechanisms and improving diagnostic approaches in infectious diseases and immunological disorders.

Publication Top Notes

Investigation of oxidative stress in patient with Varicella Zoster Virus (VZV) infection

Human genetic variation susceptibility associated with HBV: analysis of genetic markers susceptibility to hepatitis b among patients in babylon province

Genetic study of TORCH infections in women with bad obstetric history: multiplex polymerase chain reaction for detection of common pathogens and agents of congenital infections

Evaluation of CD4 and CD8 in Patients Infected with Genital Wart Caused by Human Papilloma Virus in Babylon Province/Iraq

Evaluation of serum IgE, TNF alpha at patients with genital warts, Iraq.

Immunological Study for Patient with Verruca Vulgaris and Verruca Plana Caused by HPV in Hilla/Iraq

The effect of manganese poisoning on the histological structure of testis in male Swiss mice

Bacteriological Study of Tonsillitis Patients and Estimation of Concentrations of Certain Immunological Parameters.

The distribution of antimicrobial resistance and the presence of virulence genes in Escherichia coli isolated from frozen chicken meat in Iraq

KYU SHIK MUN | Personalized Medicine | Best Researcher Award

Published on 11/03/202511/03/2025 by Top Pharmaceutical

KYU SHIK MUN | Personalized Medicine | Best Researcher Award

Assist. Prof. Dr. KYU SHIK MUN, Cedars-Sinai Medical Center, United States

Assist. Prof. Dr. Kyu Shik Mun is a distinguished researcher in cystic fibrosis (CF) and biomedical engineering 🧬. As a Principal Investigator and Co-Director, he has led groundbreaking projects on CF-related diabetes, organ-on-a-chip models, and personalized CF therapy 🏥. His work, funded by organizations like the Cystic Fibrosis Foundation and Vertex Pharmaceuticals, has yielded significant patents and high-impact publications 📑. With 733 citations, an h-index of 10, and an i10-index of 10, Dr. Mun continues to drive innovations in CF research, bridging biomedical science and translational medicine 🔬.

Publication Profile

Google Scholar

Professional Background

Assist. Prof. Dr. Kyu Shik Mun earned his Ph.D. in the Materials Science and Engineering Program at the University of Cincinnati 🎓. In 2016, he joined the Cystic Fibrosis Research Center at Cincinnati Children’s Hospital, where he pioneered a microfluidic-based organ-on-chip program from scratch 🏥🧬. His groundbreaking research focused on studying cystic fibrosis and related disorders. In 2021, he was promoted to Assistant Professor at Cedars-Sinai 🏆, where he continues to advance in vitro cell culture models using organ-on-chip technology and 3D bioprinting 🖨️🔬, contributing to innovative solutions in biomedical research and personalized medicine.

Awards

Assist. Prof. Dr. Kyu Shik Mun has received numerous prestigious honors and awards throughout his academic and professional journey 🎖️. He was awarded multiple Outstanding Grade Scholarships at Gangneung National University 🏅 (2000–2009) and recognized for excellence with department and presidential awards 🏆. His achievements include a scholarship from the Korean Broadcasting System 📺 and the Korea Research Foundation 🌏. During his Ph.D. at the University of Cincinnati, he earned a University Graduate Scholarship 🎓 (2010–2014). His research has been recognized by the American Gastroenterological Association and the Cystic Fibrosis Foundation 🧬, receiving multiple Best Abstract and Early Career Investigator awards (2017–2024) 🥇.

Experience

Assist. Prof. Dr. Kyu Shik Mun has been actively involved in non-clinical teaching, contributing to journal clubs and lab mentoring 📚🎤. He has delivered key presentations on organ-on-a-chip technology 🧬, including talks at Cincinnati Children’s Hospital (2020) and Cedars-Sinai (2021) 🏥. His mentorship spans postdoctoral fellows, research associates, and Ph.D. students, guiding projects in 3D bioprinting 🖨️ and patient-derived lung-on-a-chip models 🌬️. Since 2016, he has mentored 15 summer and rotation students—including high school, college, Ph.D., and MD candidates—on fabricating organ-on-a-chips and culturing cells, fostering the next generation of biomedical researchers 🔬.

Research Focus

Assist. Prof. Dr. Kyu Shik Mun’s research primarily focuses on nanotechnology 🧪, biosensors 🧫, and biomedical engineering 🏥. His work spans optical interferometric biosensors for label-free detection, organ-on-a-chip models for diseases like cystic fibrosis 🫁, and TiO₂ nanotube arrays for applications in solar cells ☀️ and photocatalysis. He also explores drug discovery 💊 by targeting molecular pathways in cystic fibrosis and related disorders. His interdisciplinary research integrates materials science 🏗️, biophysics ⚛️, and microfluidics 🔬 to develop innovative medical technologies, aiming to advance precision medicine 🎯 and renewable energy solutions 🌱.

Publication Top Notes

A Stable, Label-free Optical Interferometric Biosensor Based on TiO₂ Nanotube Arrays

Patient-derived pancreas-on-a-chip to model cystic fibrosis-related disorders

Guided construction of single cell reference for human and mouse lung

Targeting the pregnane X receptor using microbial metabolite mimicry

Personalized medicine in CF: from modulator development to therapy for cystic fibrosis patients with rare CFTR mutations

Surface passivation of highly ordered TiO2 nanotube arrays and application to dye-sensitized solar cells using the concept of isoelectric point

Targeting DNAJB9, a novel ER luminal co-chaperone, to rescue ΔF508-CFTR

Guanylate cyclase 2C agonism corrects CFTR mutants

Cystic Fibrosis Human Organs-on-a-Chip